SI3677252T1 - Sheme odmerjanja za spojine iz razreda ehinokandinov - Google Patents

Sheme odmerjanja za spojine iz razreda ehinokandinov

Info

Publication number
SI3677252T1
SI3677252T1 SI201332060T SI201332060T SI3677252T1 SI 3677252 T1 SI3677252 T1 SI 3677252T1 SI 201332060 T SI201332060 T SI 201332060T SI 201332060 T SI201332060 T SI 201332060T SI 3677252 T1 SI3677252 T1 SI 3677252T1
Authority
SI
Slovenia
Prior art keywords
dosing regimens
class compounds
echinocandin class
echinocandin
compounds
Prior art date
Application number
SI201332060T
Other languages
English (en)
Inventor
Balasingam Radhakrishnan
Kenneth Duke James
Anuradha Vaidya
Karen Polowy
Original Assignee
Cidara Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics, Inc. filed Critical Cidara Therapeutics, Inc.
Publication of SI3677252T1 publication Critical patent/SI3677252T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
SI201332060T 2012-03-19 2013-03-14 Sheme odmerjanja za spojine iz razreda ehinokandinov SI3677252T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612676P 2012-03-19 2012-03-19
US201261707142P 2012-09-28 2012-09-28
EP19210051.9A EP3677252B1 (en) 2012-03-19 2013-03-14 Dosing regimens for echinocandin class compounds

Publications (1)

Publication Number Publication Date
SI3677252T1 true SI3677252T1 (sl) 2024-02-29

Family

ID=49223234

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201331648T SI2827710T1 (sl) 2012-03-19 2013-03-14 Režimi odmerjanja za spojine razreda ehinokandin
SI201332060T SI3677252T1 (sl) 2012-03-19 2013-03-14 Sheme odmerjanja za spojine iz razreda ehinokandinov

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201331648T SI2827710T1 (sl) 2012-03-19 2013-03-14 Režimi odmerjanja za spojine razreda ehinokandin

Country Status (23)

Country Link
US (4) US9526835B2 (sl)
EP (2) EP3677252B1 (sl)
JP (3) JP6117907B2 (sl)
KR (2) KR102061486B1 (sl)
CN (2) CN107375898A (sl)
AU (4) AU2013235512B2 (sl)
CA (1) CA2867132A1 (sl)
CY (1) CY1122786T1 (sl)
DK (2) DK2827710T3 (sl)
ES (2) ES2767576T3 (sl)
FI (1) FI3677252T3 (sl)
HK (2) HK1206202A1 (sl)
HR (2) HRP20231151T1 (sl)
HU (2) HUE063336T2 (sl)
IL (3) IL234505A (sl)
LT (2) LT3677252T (sl)
MX (1) MX2014011299A (sl)
PL (2) PL2827710T3 (sl)
PT (2) PT3677252T (sl)
RS (2) RS59960B1 (sl)
RU (1) RU2639483C2 (sl)
SI (2) SI2827710T1 (sl)
WO (1) WO2013142279A1 (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2801155A1 (en) 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system
JP2011506319A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
HUE063336T2 (hu) 2012-03-19 2024-01-28 Cidara Therapeutics Inc Adagolási rend echinokandin osztályba tartozó vegyületekhez
CN104394903B (zh) * 2012-12-14 2017-08-15 甘布罗伦迪亚股份公司 生物流体的净化
EP2983468A4 (en) 2013-03-15 2016-09-07 Durect Corp COMPOSITIONS WITH RHEOLOGY MODIFIER TO REDUCE RESOLUTION VARIABILITY
EP3058958B1 (en) * 2015-02-23 2018-09-19 Selectchemie AG Anidulafungin composition
US10799479B2 (en) 2015-04-10 2020-10-13 Bioresponse, L.L.C. Self-emulsifying formulations of DIM-related indoles
WO2016201283A1 (en) * 2015-06-12 2016-12-15 Cidara Therapeutics, Inc. Antifungal agents
US20180256673A1 (en) * 2015-09-16 2018-09-13 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2017049105A1 (en) * 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations for treating fungal infections
EP3399995A4 (en) * 2016-01-08 2019-08-21 Cidara Therapeutics, Inc. METHODS FOR PREVENTING AND TREATING PNEUMOCYSTIS INFECTIONS
ES2955711T3 (es) * 2016-03-16 2023-12-05 Cidara Therapeutics Inc Regímenes de dosificación para el tratamiento de infecciones fúngicas
KR101937531B1 (ko) * 2016-09-28 2019-01-10 국립암센터 대장암 진단 장치와 대장암 진단 정보 제공 방법
MA47437A (fr) * 2017-01-31 2019-12-11 Cidara Therapeutics Inc Procédés de traitement d'infections fongiques
MX2019014539A (es) * 2017-06-05 2020-02-10 Flagship Pioneering Innovations V Inc Agentes multibioticos y metodos para utilizarlos.
MA49576A (fr) * 2017-07-12 2021-04-07 Cidara Therapeutics Inc Compositions et méthodes pour le traitement d'infections fongiques
JP7373508B2 (ja) 2018-06-15 2023-11-02 シダラ セラピューティクス インコーポレーテッド エキノカンジン抗真菌剤の合成
CN110655557A (zh) * 2018-06-28 2020-01-07 浙江医药股份有限公司新昌制药厂 一种纽莫康定b0丝氨酸类似物的分离纯化方法
CN111380974A (zh) * 2018-12-30 2020-07-07 山东新时代药业有限公司 一种棘白菌素的检测方法
US20210022948A1 (en) * 2019-07-22 2021-01-28 Ismail Mohammed Yousif Musallam Neuromodulation for treatment of retinal, choroidal and optic nerve disorders and/or dysregulated reduced ocular blood flow (obf)
EP4349851A1 (en) * 2021-06-03 2024-04-10 Shanghai Senhui Medicine Co., Ltd. Method for preparing anidulafungin derivative
US11559495B1 (en) * 2022-03-07 2023-01-24 King Abdulaziz University Icariin nano-pharmaceutical formulation

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6030944A (en) * 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
CH682806A5 (de) 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
MY136593A (en) * 1992-03-19 2008-10-31 Lilly Co Eli Cyclic peptide antifungal agents and process for preparation thereof
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
EP0697879A4 (en) * 1993-05-04 1998-01-14 Merck & Co Inc AMINOALKYL ETHERS OF CYCLOHEXAPEPTIDYLE
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
AU7874494A (en) * 1993-09-22 1995-04-10 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5541160A (en) 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
CA2211138A1 (en) 1995-01-26 1996-08-01 Merck & Co., Inc. Novel antifungal cyclohexapeptides
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5665389A (en) 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
PE63998A1 (es) * 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
US6069126A (en) 1996-09-12 2000-05-30 Merck & Co., Inc. Antifungal combination therapy
US5945510A (en) 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
US6459857B2 (en) 1998-03-11 2002-10-01 Nikon Corporation Electronic camera
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US6733762B1 (en) 1998-09-14 2004-05-11 University Of Maryland, Baltimore Method of using Zot to inhibit lymphocyte proliferation in an antigen-specific manner
US6597946B2 (en) 1998-11-09 2003-07-22 Transpharma Ltd. Electronic card for transdermal drug delivery and analyte extraction
US6611706B2 (en) 1998-11-09 2003-08-26 Transpharma Ltd. Monopolar and bipolar current application for transdermal drug delivery and analyte extraction
US6708060B1 (en) 1998-11-09 2004-03-16 Transpharma Ltd. Handheld apparatus and method for transdermal drug delivery and analyte extraction
US6148232A (en) 1998-11-09 2000-11-14 Elecsys Ltd. Transdermal drug delivery and analyte extraction
ES2272096T3 (es) 1998-12-09 2007-04-16 Eli Lilly And Company Purificacion de compuestos ciclopeptidicos de equinocandina.
US6275728B1 (en) 1998-12-22 2001-08-14 Alza Corporation Thin polymer film drug reservoirs
CA2355860C (en) 1998-12-23 2010-03-30 Alza Corporation Dosage forms comprising porous particles
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
CA2362482A1 (en) 1999-03-03 2000-09-08 Eli Lilly And Company Processes for making pharmaceutical oral ecb formulations and compositions
WO2000051564A1 (en) * 1999-03-03 2000-09-08 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
US6309622B1 (en) 1999-03-26 2001-10-30 Protech Professional Products, Inc. Antimicrobial denture cleansing compositions
JP3777499B2 (ja) 1999-04-16 2006-05-24 ゼファーマ株式会社 抗真菌組成物
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6610822B2 (en) 2000-09-01 2003-08-26 Merck & Co., Inc. Purification process
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
ES2315312T3 (es) 2000-11-01 2009-04-01 Merck Patent Gmbh Procedimiento y composiciones para el tratamiento de enfermedades del ojo.
CA2452056C (en) 2001-07-02 2011-11-01 Elan Corporation, Plc. Compositions of bioactive material particles dispersed in a continuous solid encapsulating material
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
DE10212609B4 (de) 2002-03-21 2015-03-26 Epcos Ag Elektrolytlösung und deren Verwendung
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
CA2502148A1 (en) 2002-10-16 2005-02-17 Board Of Regents, The University Of Texas System Methods and compositions for increasing the efficacy of biologically-active ingredients
US6913759B2 (en) 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
ES2298821T3 (es) 2003-07-22 2008-05-16 Theravance, Inc. Utilizacion de un agente antifungico de equinocandina en combinacion con un agente antibacteriano glicopeptidico.
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
US7541219B2 (en) 2004-07-02 2009-06-02 Seagate Technology Llc Integrated metallic contact probe storage device
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US20060062758A1 (en) 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
WO2006076692A1 (en) 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
US8753819B2 (en) 2005-07-26 2014-06-17 Rutgers, The State University Of New Jersey Assays for resistance to echinocandin-class drugs
JP5222727B2 (ja) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
FI20055503A0 (fi) 2005-09-20 2005-09-20 Fennopharma Oy Uudet kvaternääriset polymeerit
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
US20070231258A1 (en) 2006-03-31 2007-10-04 Karyon Ctt Ltd. Peptide conjugates
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
MX2011002836A (es) 2008-09-17 2011-04-28 Chiasma Inc Composiciones farmaceúticas y métodos de administración relacionados.
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
MX340791B (es) 2009-02-25 2016-07-25 Stiefel Res Australia Pty Ltd Composicion de espuma topica.
CN102421790A (zh) 2009-05-07 2012-04-18 帝斯曼知识产权资产管理有限公司 制备环肽的方法
ES2663709T3 (es) * 2009-08-26 2018-04-16 Bioelectron Technology Corporation Métodos para la prevención y el tratamiento de la isquemia cerebral
JP2013503179A (ja) * 2009-08-27 2013-01-31 シーチェイド ファーマシューティカルズ，インコーポレーテッド エキノキャンディン誘導体
EP2525831B1 (en) * 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
GB2478849A (en) 2010-03-16 2011-09-21 Chiasma Inc Improved pharmecutical compositions and methods of delivery
US8955334B2 (en) 2010-07-22 2015-02-17 General Electric Company Systems and methods for controlling the startup of a gas turbine
CN106279369B (zh) 2011-03-03 2020-02-11 奇达拉治疗公司 抗真菌剂及其应用
EP2739652B1 (en) 2011-08-04 2017-04-05 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
US8829053B2 (en) 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
HUE063336T2 (hu) 2012-03-19 2024-01-28 Cidara Therapeutics Inc Adagolási rend echinokandin osztályba tartozó vegyületekhez
CN102766198A (zh) 2012-05-04 2012-11-07 中国人民解放军第二军医大学 一种糖肽类抗真菌化合物及其制备方法与应用
US20150320675A1 (en) 2013-01-18 2015-11-12 University Of Utah Research Foundation Modified Release Osmotic Pump for PH-Responsive Drug Delivery
WO2014124504A1 (en) 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions and methods for treating biofilms
US9919055B2 (en) 2013-03-15 2018-03-20 Arizona Board Of Regents On Behalf Of Arizona State University Sugar-linker-drug conjugates
CA2910752C (en) 2013-05-01 2021-11-23 Neoculi Pty Ltd Use of robenidine in the treatment of bacterial infection
US20160213742A1 (en) 2013-09-04 2016-07-28 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
US20180256673A1 (en) 2015-09-16 2018-09-13 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2017049105A1 (en) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations for treating fungal infections
EP3399995A4 (en) 2016-01-08 2019-08-21 Cidara Therapeutics, Inc. METHODS FOR PREVENTING AND TREATING PNEUMOCYSTIS INFECTIONS
ES2955711T3 (es) 2016-03-16 2023-12-05 Cidara Therapeutics Inc Regímenes de dosificación para el tratamiento de infecciones fúngicas
WO2018085200A1 (en) 2016-11-01 2018-05-11 Cidara Therapeutics, Inc. Single dose methods for preventing and treating fungal infections
WO2018102407A1 (en) 2016-11-29 2018-06-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
MA47437A (fr) 2017-01-31 2019-12-11 Cidara Therapeutics Inc Procédés de traitement d'infections fongiques
WO2018187574A1 (en) 2017-04-05 2018-10-11 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2018191692A1 (en) 2017-04-14 2018-10-18 Cidara Therapeutics, Inc. Methods for treating fungal infections
MA49576A (fr) 2017-07-12 2021-04-07 Cidara Therapeutics Inc Compositions et méthodes pour le traitement d'infections fongiques
US20200164023A1 (en) 2017-08-03 2020-05-28 Cidara Therapeutics, Inc. Methods for preventing and treating intra-abdominal candidiasis
JP7373508B2 (ja) * 2018-06-15 2023-11-02 シダラ セラピューティクス インコーポレーテッド エキノカンジン抗真菌剤の合成

Also Published As

Publication number Publication date
IL254067B (en) 2020-06-30
PL3677252T3 (pl) 2024-01-08
AU2013235512A2 (en) 2015-01-15
EP2827710A1 (en) 2015-01-28
HK1206202A1 (en) 2016-01-08
CN104507309A (zh) 2015-04-08
RU2014141791A (ru) 2016-05-10
JP6386609B2 (ja) 2018-09-05
ES2767576T3 (es) 2020-06-18
US20170151306A1 (en) 2017-06-01
RS59960B1 (sr) 2020-03-31
JP2017171658A (ja) 2017-09-28
JP6117907B2 (ja) 2017-04-19
IL234505A (en) 2017-08-31
EP2827710A4 (en) 2015-11-25
IL274829B (en) 2021-12-01
DK2827710T3 (da) 2020-02-03
LT3677252T (lt) 2023-10-10
WO2013142279A1 (en) 2013-09-26
US9526835B2 (en) 2016-12-27
KR20140138976A (ko) 2014-12-04
US11654196B2 (en) 2023-05-23
JP6731980B2 (ja) 2020-07-29
AU2013235512B2 (en) 2016-12-15
ES2957620T3 (es) 2024-01-23
AU2013235512A1 (en) 2014-09-25
EP2827710B1 (en) 2019-11-20
IL254067A0 (en) 2017-10-31
AU2017201758A1 (en) 2017-04-06
US20210128670A1 (en) 2021-05-06
HUE047439T2 (hu) 2020-04-28
PL2827710T3 (pl) 2020-05-18
AU2017201758B2 (en) 2018-11-15
HRP20231151T1 (hr) 2024-01-05
US10702573B2 (en) 2020-07-07
RS64862B1 (sr) 2023-12-29
AU2020256337A1 (en) 2020-11-12
AU2019201072B2 (en) 2020-07-16
FI3677252T3 (fi) 2023-09-29
EP3677252B1 (en) 2023-06-28
JP2018188471A (ja) 2018-11-29
AU2020256337B2 (en) 2022-06-09
US20150087583A1 (en) 2015-03-26
RU2639483C2 (ru) 2017-12-21
MX2014011299A (es) 2015-05-11
CN104507309B (zh) 2017-05-03
HRP20200072T1 (hr) 2020-04-03
HUE063336T2 (hu) 2024-01-28
HK1206935A1 (en) 2016-01-22
CN107375898A (zh) 2017-11-24
DK3677252T3 (da) 2023-10-02
US10016479B2 (en) 2018-07-10
KR102236462B1 (ko) 2021-04-08
KR102061486B1 (ko) 2020-01-03
EP3677252A1 (en) 2020-07-08
CY1122786T1 (el) 2021-05-05
KR20200003423A (ko) 2020-01-09
LT2827710T (lt) 2020-02-10
US20190160141A1 (en) 2019-05-30
SI2827710T1 (sl) 2020-04-30
CA2867132A1 (en) 2013-09-26
PT3677252T (pt) 2023-10-02
AU2019201072A1 (en) 2019-03-07
PT2827710T (pt) 2020-02-25
JP2015512392A (ja) 2015-04-27
IL274829A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
HK1206935A1 (en) Dosing regimens for echinocandin class compounds
HK1256106A1 (zh) 抗α4β7抗體的給藥方案
ZA201902009B (en) Anti-folr1 immunocunjugate dosing regimens
EP2775987A4 (en) LOADING BOTTLES
HK1202543A1 (en) Azaheterocyclic compounds
HK1205557A1 (en) Devices for determining photoprotective materials
GB201205164D0 (en) Pharmaceutical compounds
GB2506432B (en) Devices for Blending Materials
GB201218012D0 (en) Dosage forms
HK1216619A1 (zh) 藥物化合物
PL2841885T3 (pl) Urządzenie dozujące
HK1205084A1 (en) Dosing dispenser
GB201202027D0 (en) Pharmaceutical compounds
EP2864414A4 (en) PVC-ACRYLATE MIXTURES
GB201208536D0 (en) Dosing regimen
AU348739S (en) Dosage container
AU348737S (en) Dosage container
AU348740S (en) Dosage container
GB201219236D0 (en) Pharmaceutical compounds
GB201214121D0 (en) Pharmaceutical compounds
GB201213519D0 (en) Pharmaceutical compounds
GB201203253D0 (en) Pharmaceutical compounds
GB201211308D0 (en) Compounds for use
GB201206221D0 (en) Materials for devices